Drug profile · INN
vepdegestrant
VEPPANU
- US status
- approved
- Patents linked
- 0
- News articles
- 3
Quick answer
vepdegestrant (VEPPANU) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
Related news
Rigel Pharmaceuticals Licenses FDA-Approved Breast Cancer Drug VEPPANU
Rigel Pharmaceuticals' stock surged by 11.4% following the licensing of VEPPANU, an FDA-approved breast cancer drug. This move signals significant potential for growth in the oncology market.
Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer
Arvinas' VEPPANU becomes the first FDA-approved PROTAC drug for ESR1-mutated, ER+/HER2- advanced breast cancer, marking a breakthrough in protein degradation therapy.
Arvinas Receives FDA Approval for VEPPANU (Vepdegestrant), First PROTAC Drug for ESR1-Mutated Breast Cancer
Arvinas announces FDA approval of VEPPANU, the first PROTAC protein degrader for ESR1-mutated, ER+/HER2- advanced breast cancer treatment.
Frequently asked questions
What is vepdegestrant?
vepdegestrant (VEPPANU) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for vepdegestrant?
VEPPANU is a marketed brand name for vepdegestrant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vepdegestrant?
vepdegestrant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.